The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
Open accessAbstract
Purpose: Patients with metastatic gastric cancer (mGC) who do not respond to or who experience progression with second-line chemotherapy have no treatment options that clearly confer a survival benefit. This trial investigated the safety and efficacy of apatinib, an inhibitor of vascular endothelial growth factor receptor, as a treatment option for heavily pretreated patients with mGC. Patients and Methods: Patients who experienced treatment failure with at least two chemotherapeutic regimens were randomly assigned to receive placebo (group A), apatinib 850 mg once daily (group B), or apatinib 425 mg twice daily (group C). Results: We enrolled 144 patients onto this study. In groups A, B, and C, the median overall survival (OS) times were 2.50 months (95% CI, 1.87 to 3.70 months), 4.83 months (95% CI, 4.03 to 5.97 months), and 4.27 months (95% CI, 3.83 to 4.77 months), respectively, and the median progression-free survival (PFS) times were 1.40 months (95% CI, 1.20 to 1.83 months), 3.67 months (95% CI, 2.17 to 6.80 months), and 3.20 months (95% CI, 2.37 to 4.53 months), respectively. There were statistically significant differences between the apatinib and placebo groups for both PFS (P < .001) and OS (P < .001 and P = .0017). Nine patients had a partial response (three patients in group B and six patients in group C). Toxicities were tolerable or could be clinically managed. The most common grade 3 to 4 adverse events were hand-foot syndrome and hypertension. Hematologic toxicities were moderate, and grade 3 to 4 hematologic toxicities were rare. Conclusion: Apatinib showed improved PFS and OS in heavily pretreated patients with mGC who had experienced treatment failure with two or more chemotherapy regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Kang, J. H., Lee, S. I., Lim, D. H., Park, K.-W., Oh, S. Y., Kwon, H.-C., Hwang, I. G., Lee, S.-C., Nam, E., Shin, D. B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4585 · Cited by 660
Tian, S., Quan, H., Xie, C., Guo, H., Lü, F., Xu, Y., Li, J., & Lou, L. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01939.x · Cited by 513
Self-citationVan Cutsem, E., de Haas, S., Kang, Y.-K., Ohtsu, A., Tebbutt, N. C., Ming Xu, J., Peng Yong, W., Langer, B., Delmar, P., Scherer, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9824 · Cited by 477
Li, J., Zhao, X., Chen, L., Guo, H., Lv, F., Jia, K., Yv, K., Wang, F., Li, C., Qian, J., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-529 · Cited by 265
Self-citationPhase II study of sunitinib as second-line treatment for advanced gastric cancer
Bang, Y.-J., Kang, Y.-K., Kang, W. K., Boku, N., Chung, H. C., Chen, J.-S., Doi, T., Sun, Y., Shen, L., Qin, S., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9438-y · Cited by 193
Self-citationTanigawa, N., Amaya, H., Matsumura, M., & Shimomatsuya, T. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.826 · Cited by 172
Lee, J., Lim, T., Uhm, J. E., Park, K. W., Park, S. H., Lee, S. C., Park, J. O., Park, Y. S., Lim, H. Y., Sohn, T. S., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl501 · Cited by 169
Translation and validation of the Standard Chinese version of the EORTC QLQ-C30
Zhao, H., & Kanda, K. (2000) · Quality of Life Research · doi:10.1023/a:1008981520920 · Cited by 150
Kang, Y., Ohtsu, A., Cutsem, E. V., Rha, S. Y., Sawaki, A., Park, S., Lim, H. Y., Wu, J., Langer, B., & Shah, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.18_suppl.lba4007 · Cited by 110
Thuss-Patience, P. C., Hofheinz, R., Arnold, D., Florschütz, A., Daum, S., Kretzschmar, A., Mantovani‐Löffler, L., Bichev, D., Breithaupt, K., Kneba, M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds129 · Cited by 72
Cited by
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., Liu, W., Tong, J., Liu, Y., Xu, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5995 · Cited by 972
Self-citationFord, H. E. R., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., Mansoor, W., Fyfe, D., Madhusudan, S., Middleton, G. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70549-7 · Cited by 595
Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
Liu, K., Ren, T., Huang, Y., Sun, K., Bao, X., Wang, S., Zheng, B., & Guo, W. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.422 · Cited by 264
Self-citationHu, X., Zhang, J., Xu, B., Jiang, Z., Ragaz, J., Tong, Z., Zhang, Q., Wang, X., Feng, J., Pang, D., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28829 · Cited by 264
Self-citation
Metadata
- Authors
- Li, J., Qin, S., Xu, J., Guo, W., Xiong, J., Bai, Y., Sun, G., Yang, Y., Wang, L., Xu, N., Cheng, Y., Wang, Z., Zheng, L., Tao, M., Zhu, X., Ji, D., Liu, X., & Yu, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-09-10
- Volume
- 31
- Issue
- 26
- Pages
- 3219-3225
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113935263
- Cited by
- 533
- References
- 12
- FWCI
- 24.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.